Ephedrine

ID: ephedrine

Aliases: ephedrine HCl

Type: compound

Route/form: oral

Status: regulated_or_prescription_context_dependent

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human, review/regulatory

Source types: evidence_report, human_physiology

Linked sources: 2

Broad outcomes: Fat loss / metabolic health, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• sympathomimetic
• adrenergic agonist

Optimization domains

• fat loss
• stimulant
• bronchodilator

Research basis

• Human evidence supports stimulant/thermogenic and appetite-suppression effects, especially with caffeine.
• The mechanism is straightforward sympathomimetic physiology rather than an obscure target claim.
• Evidence-report data provide adverse-event context alongside efficacy.

Limits, risks, and missing evidence

• Blood pressure, arrhythmia, anxiety, insomnia, heat stress, and interaction burden are major constraints.
• It is a poor fit for uncontrolled hypertension or physical panic symptoms.
• Short-term thermogenesis does not equal a low-risk long-term fat-loss strategy.

Risk flags

• cardiovascular
• stimulant
• drug interactions

Linked papers, labels, and reviews

1. Ephedra and ephedrine for weight loss and athletic performance enhancement
   evidence_report / ahrq_ephedrine_weight_loss_2003
   AHRQ evidence report summary covering efficacy and adverse events, including cardiovascular/autonomic safety concerns.
2. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine
   human_physiology / pubmed_ephedrine_caffeine_2004
   Randomized crossover human physiology study of combined ephedrine and caffeine stimulant/metabolic effects.